StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does STME (STME) operate in?
STME belongs to the Other sector and operates in the Medical Devices industry.
What is STME (STME) current stock price?
As of the latest data, STME stock price is $0.15, with a previous close of $0.15.
What is STME (STME) current market capitalization?
STME market cap is approximately 3.11 million.
What is STME (STME) Earnings Per Share (EPS)?
The trailing EPS is -$0.03, and the forward EPS is -$0.02.
What is STME (STME) EBITDA?
STME EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -139.85 thousand.
Does STME (STME) pay dividends?
No. STME does not pay a dividend.
What is STME (STME) beta (volatility) score?
STME has a beta of 46.006, indicating very high volatility compared to the market.
